Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CVAC
stocks logo

CVAC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
13.35M
-7.93%
-0.090
-35.71%
0.00
-100%
0.000
-100%
0.00
-100%
0.000
-100%
Estimates Revision
The market is revising Downward the revenue expectations for CureVac N.V. (CVAC) for FY2025, with the revenue forecasts being adjusted by -0.47% over the past three months. During the same period, the stock price has changed by -5.01%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.47%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-17.31%
In Past 3 Month
Stock Price
Go Down
down Image
-5.01%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for CureVac NV (CVAC.O) is -8.66, compared to its 5-year average forward P/E of -9.78. For a more detailed relative valuation and DCF analysis to assess CureVac NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.78
Current PE
-8.66
Overvalued PE
3.29
Undervalued PE
-22.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-10.10
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.01
Undervalued EV/EBITDA
-23.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
30.72
Current PS
0.00
Overvalued PS
73.77
Undervalued PS
-12.33
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CVAC News & Events

Events Timeline

(ET)
2025-12-03
09:10:00
BioNTech Completes CureVac Acquisition with 184,071,410 Shares Validly Tendered
select
2025-11-26 (ET)
2025-11-26
07:33:14
BioNTech Provides Update on Its Exchange Offer for CureVac Shares
select
2025-11-24 (ET)
2025-11-24
07:51:10
CureVac anticipates funding will last until 2028
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-03Globenewswire
BioNTech Acquires 81.74% of CureVac Shares in Exchange Offer
  • Acquisition Progress: BioNTech successfully acquired 184,071,410 shares of CureVac, representing approximately 81.74% of its issued shares, satisfying the minimum condition for the exchange offer and marking a significant advancement in the acquisition process.
  • Subsequent Arrangements: The subsequent offering period has commenced and will expire on December 18, 2025, allowing CureVac shareholders who have not yet tendered their shares to do so, further facilitating the completion of the transaction.
  • Shareholder Impact: Non-tendering shareholders will receive BioNTech American Depositary Shares in the post-offer reorganization, which may be subject to a 15% Dutch dividend withholding tax, potentially affecting their investment returns.
  • Market Reaction: This acquisition is expected to further solidify BioNTech's market position in the biopharmaceutical sector, likely driving the development and market expansion of its innovative therapies.
[object Object]
Preview
8.5
12-03Newsfilter
BioNTech Acquires 81.74% of CureVac Shares in Exchange Offer
  • Acquisition Progress: BioNTech has successfully acquired 81.74% of CureVac's shares, satisfying the minimum condition for the exchange offer, which signifies further consolidation and expansion in the biopharmaceutical sector.
  • Subsequent Offer Period: The subsequent offering period has commenced and will expire on December 18, 2025, allowing CureVac shareholders who have not yet tendered their shares to do so, enhancing the transaction's flexibility and appeal.
  • Tax Implications: Non-tendering CureVac shareholders will face a 15% Dutch dividend withholding tax during the post-offer reorganization, which may impact their investment returns and requires careful consideration.
  • Market Reaction: This acquisition is expected to significantly enhance BioNTech's competitiveness in the global biopharmaceutical market, particularly in the field of cancer immunotherapy, likely driving its future R&D and market expansion efforts.
[object Object]
Preview
8.5
11-26SeekingAlpha
BioNTech's Proposal to Acquire German mRNA Vaccine Competitor CureVac Will End on December 3

  • BioNTech's Acquisition of CureVac: BioNTech SE announced the approval of its exchange offer for all outstanding shares of CureVac N.V. at an extraordinary general meeting, with over 99.16% of CureVac shareholders voting in favor.

  • Transaction Details: The acquisition, valued at nearly $1.25 billion, is expected to be completed as soon as reasonably practicable, with the offer set to expire on December 3.

  • Shareholder Instructions: CureVac shareholders are advised to tender their shares by 6:00 pm Eastern Time on December 2 to meet operational deadlines.

  • Additional Context: The article also mentions BioNTech's ongoing strategies in oncology and its financial status, alongside Pfizer's plans to divest its remaining stake in BioNTech.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CureVac NV (CVAC) stock price today?

The current price of CVAC is 5.12 USD — it has decreased -0.78 % in the last trading day.

arrow icon

What is CureVac NV (CVAC)'s business?

CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

arrow icon

What is the price predicton of CVAC Stock?

Wall Street analysts forecast CVAC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVAC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CureVac NV (CVAC)'s revenue for the last quarter?

CureVac NV revenue for the last quarter amounts to 54.13M USD, decreased -89.04 % YoY.

arrow icon

What is CureVac NV (CVAC)'s earnings per share (EPS) for the last quarter?

CureVac NV. EPS for the last quarter amounts to 1.21 USD, decreased -19.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for CureVac NV (CVAC)'s fundamentals?

The market is revising Downward the revenue expectations for CureVac N.V. (CVAC) for FY2025, with the revenue forecasts being adjusted by -0.47% over the past three months. During the same period, the stock price has changed by -5.01%.
arrow icon

How many employees does CureVac NV (CVAC). have?

CureVac NV (CVAC) has 825 emplpoyees as of December 05 2025.

arrow icon

What is CureVac NV (CVAC) market cap?

Today CVAC has the market capitalization of 1.15B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free